S.2126 - Regenerative Medicine Promotion Act of 2014113th Congress (2013-2014)
|Sponsor:||Sen. Boxer, Barbara [D-CA] (Introduced 03/13/2014)|
|Committees:||Senate - Health, Education, Labor, and Pensions|
|Latest Action:||Senate - 03/13/2014 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.2126 — 113th Congress (2013-2014)All Information (Except Text)
Introduced in Senate (03/13/2014)
Regenerative Medicine Promotion Act of 2014 - Requires the Comptroller General to submit to Congress a report identifying all ongoing federal programs and activities regarding regenerative medicine.
Directs the Secretary of Health and Human Services (HHS) to establish a Regenerative Medicine Coordinating Council, which shall:
- prepare a national strategy to support research into regenerative medicine and enable the development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine;
- develop national goals for regenerative medicine research and product development;
- prepare a plan specifying priorities for research into regenerative medicine;
- identify sources of funding for research into regenerative medicine and areas where such funding is inadequate or duplicative;
- make recommendations regarding federal policies to support development and marketing of regenerative medicine products;
- develop consensus standards regarding scientific issues critical to regulator approval of regenerative medicine products; and
- determine the need for establishing centers of excellence or consortia to further advance regenerative medicine.
Directs the Council to: (1) adopt procedures to ensure the receipt of public input; and (2) submit an annual report on its activities to Congress, the Director of the National Institutes of Health (NIH), and the Commissioner of Food and Drugs (FDA).